Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial - Concepedia

Concepedia

Publication | Closed Access

Effect of Endothelin-A Receptor Blockade With Atrasentan on Tumor Progression in Men With Hormone-Refractory Prostate Cancer: A Randomized, Phase II, Placebo-Controlled Trial

370

Citations

33

References

2003

Year

Michael A. Carducci, Robert J. Padley, Jürgen Breul, Nicholas J. Vogelzang, Bernard A. Zonnenberg, Danai Daliani, Claude C. Schulman, Azmi Nabulsi, Rod Humerickhouse, Mark Weinberg,

Journal of Clinical Oncology

Abstract

Atrasentan is an oral, targeted therapy with favorable tolerability and the potential to delay progression of HRPCa.

References

	Year	Citations

Page 1